Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
5.28
-0.28 (-5.04%)
At close: Oct 31, 2024, 4:00 PM
5.24
-0.04 (-0.75%)
After-hours: Oct 31, 2024, 6:38 PM EDT

Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.

Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.

The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals logo
Country United States
Founded 1979
IPO Date Feb 12, 1998
Industry Biotechnology
Sector Healthcare
Employees 122
CEO Jacqueline Shea

Contact Details

Address:
660 West Germantown Pike, Suite 110
Plymouth Meeting, Pennsylvania 19462
United States
Phone 267 440 4200
Website inovio.com

Stock Details

Ticker Symbol INO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001055726
CUSIP Number 45773H201
ISIN Number US45773H4092
Employer ID 33-0969592
SIC Code 3841

Key Executives

Name Position
Dr. Jacqueline E. Shea Ph.D. Chief Executive Officer, President and Director
Peter D. Kies Chief Financial Officer
Dr. Laurent M. Humeau Ph.D. Chief Scientific Officer and Chairman of the Scientific Advisory Board
Thomas Hong Manager of Investor Relations
Robert L. Crotty J.D. General Counsel and Chief Compliance Officer
E. J. Brandreth MBA Senior Vice President of Quality Assurance
Dr. Jeffrey Skolnik Senior Vice President of Clinical Development
Robert J. Juba Jr. Senior Vice President of Biological Manufacturing and Clinical Supply Management
Stephen Kemmerrer M.B.A., P.E. Senior Vice President of Engineering Development
Shawn D. Bridy M.A., M.B.A. Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Oct 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 13, 2024 424B5 Filing
Aug 13, 2024 8-K Current Report
Aug 8, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
May 28, 2024 8-K Current Report
May 13, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
Apr 26, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Apr 17, 2024 8-K Current Report